bioAffinity Technologies, Inc. SEC filings document the public-company record for a biotechnology diagnostics issuer with Nasdaq-listed common stock and tradeable warrants. The filings identify the company as an emerging growth company and smaller reporting company and include disclosures tied to CyPath® Lung, laboratory services, operating performance, and securities registration activity.
Recent filings include Form 8-K reports for financial results, Regulation FD presentation materials, product and clinical-case announcements, and annual meeting voting results. The record also covers governance matters such as director elections and equity incentive plan amendments, along with S-1 registration materials describing securities being registered and related issuer classifications.
bioAffinity Technologies, Inc. (BIAF) is asking stockholders to vote on four proposals: approval to issue up to 1,128,272 common shares upon exercise of warrants from its private placement that closed on August 14, 2026; authorization for one or more future non-public offerings; a reduction in authorized common shares from 350,000,000 to 200,000,000; and authority to adjourn if more proxy votes are needed. The board recommends a “FOR” vote on each proposal.
The warrants have an adjusted exercise price of $4.9757 per share and become exercisable when stockholder approval takes effect. If all are exercised for cash at that price, the company says it could receive up to approximately $5.6 million in gross proceeds; issuing the shares would dilute existing holders. The proposed offering authorization is limited to 10,000,000 shares and $10,000,000 in cash consideration, with securities offered at a discount of up to 35% below market price. The authorized-share decrease would be implemented only if the board later determines it is in stockholders’ best interests, and the board may abandon it.
bioAffinity Technologies, Inc. (BIAF) reported that it will present two posters on its noninvasive lung cancer diagnostic, CyPath® Lung, at the 2026 NAVREF Annual Conference, focusing on clinical use and ongoing research in veteran and military populations, together with new distribution partner AvMEDICAL.
One poster discusses complex high-risk cases where CyPath Lung was used alongside imaging and other tests, while a second describes the ongoing 2,000-patient FlowPath™ Lung longitudinal study across 12 VA medical centers and two major military hospitals. The company highlights previously reported CyPath Lung performance in patients with pulmonary nodules of 20 mm or less, including 92% sensitivity, 87% specificity and 99% negative predictive value, and cites an independent economic analysis suggesting its test has the potential to generate substantial per-patient and overall healthcare cost savings in lung cancer screening and diagnosis.
bioAffinity Technologies, Inc. (BIAF) reports that the Hong Kong Intellectual Property Department has granted a patent for its proprietary technology used to predict the likelihood of lung cancer by applying flow cytometry and fluorescent markers to characterize cell populations in sputum. Hong Kong Patent No. HK40048460, titled “System and Method for Determining Lung Health”, covers the use of defined antibodies and the porphyrin TCPP to label sputum cell populations and detect lung cancer cells via flow cytometry. This patent builds on a 2025 patent granted in China and contributes to a broader patent estate that includes multiple patents and pending applications in the United States, Australia, Canada, China, the European Union, Japan, Mexico and Singapore, supporting the CyPath® Lung diagnostic and other pipeline tests. The company highlights CyPath Lung’s noninvasive use in high-risk patients with small indeterminate lung nodules and cites published clinical trial results showing 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in detecting lung cancer.
bioAffinity Technologies, Inc. (BIAF) reported that management has prepared investor presentation materials covering the company’s operations and performance, which may be used from time to time, including at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14–16, 2026.
The presentation materials are furnished as Exhibit 99.1 under a Regulation FD disclosure and are expressly designated as “furnished” rather than “filed,” meaning they are not subject to certain Exchange Act liabilities and are not automatically incorporated by reference into other Securities Act or Exchange Act filings.
bioAffinity Technologies, Inc. (BIAF) reports that it has regained compliance with Nasdaq’s listing requirements, including the Minimum Bid Price Rule and the Rights/Warrants Rule, so its common stock and warrants will continue to be listed and traded on the Nasdaq Capital Market.
Nasdaq confirmed compliance in a letter dated September 8, 2026, cancelling a previously scheduled hearing before a Nasdaq Hearings Panel. As of September 8, 2026, the company had 1,166,625 common shares outstanding with an aggregate market value of approximately $10.4 million based on that day’s closing price.
The company also highlights performance of its CyPath® Lung test, which in a published clinical trial of high-risk patients showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value for detecting lung cancer in patients with small indeterminate lung nodules less than 20 millimeters.
bioAffinity Technologies, Inc. (BIAF) reported that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026, and issued a related press release.
The company highlighted recent and upcoming strategic milestones, commercial adoption and momentum for its CyPath® Lung diagnostic test, and development of additional diagnostic and therapeutic applications based on its proprietary technology platform. As of September 2, 2026, there were 600,736 outstanding common shares, with an aggregate market value of approximately $5.9 million based on the Nasdaq Capital Market closing price.
bioAffinity Technologies, Inc. (BIAF) has filed an amended resale registration covering up to 1,692,408 shares of common stock issuable from previously issued Pre-Funded, Series A and Series B Warrants sold in an August 2026 private placement. All shares are being offered by selling stockholders, not by the company.
The company will not receive proceeds from resales, but could receive about $5.7 million in gross proceeds if all registered warrants are exercised for cash. Shares outstanding were 600,736 as of September 2, 2026 and would be 2,293,144 if all registered warrant shares are issued, excluding other convertible and equity award overhang.
bioAffinity develops noninvasive lung diagnostics, led by its CyPath® Lung test, and is expanding into government healthcare via a new distribution agreement with AvMEDICAL. The company recently completed a 1-for-15 reverse stock split, and its auditors have included a going concern explanatory paragraph due to recurring losses.
bioAffinity Technologies, Inc. (BIAF) reported that it is advancing the potential use of its noninvasive CyPath® Lung test for surveillance of lung cancer patients after curative-intent treatment. The company highlights a large survivorship population and positions CyPath Lung as a complement to CT imaging in monitoring pulmonary nodules for recurrence or new cancers.
CyPath Lung is a Laboratory Developed Test that analyzes sputum using flow cytometry, artificial intelligence and a fluorescent porphyrin to identify malignant and cancer-related cells. In a published trial in high-risk patients with small indeterminate nodules, CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value for early lung cancer detection, though these performance data have not been separately validated for post-treatment surveillance.
bioAffinity Technologies, Inc. (BIAF) filed a resale registration covering up to 1,709,334 shares of common stock issuable upon exercise of existing warrants sold in an August 2026 private placement. The shares may be sold from time to time by the selling stockholders, who will receive all sale proceeds.
The company will not receive proceeds from share resales, but could receive up to about $8.2 million if all warrants are exercised for cash. Warrants include 564,136 pre-funded warrants at $0.105 per share and other series at $7.0905 per share, generally exercisable for five years, subject to ownership caps. Shares outstanding were 592,327 as of August 26, 2026 and would be 2,301,661 assuming full warrant exercise. bioAffinity develops noninvasive lung diagnostics, led by its CyPath® Lung test, and is expanding distribution via a new agreement with AvMEDICAL. A 1-for-15 reverse stock split became effective August 21, 2026, and the most recent audit report includes a going-concern explanatory paragraph.
bioAffinity Technologies, Inc. (BIAF) approved and is implementing a 1-for-15 reverse stock split of its common stock. A certificate of amendment was filed in Delaware on August 20, 2026, and the split becomes effective at 4:01 p.m. Eastern Time on August 21, 2026, with trading on a split-adjusted basis on the Nasdaq Capital Market beginning August 24, 2026.
Every 15 issued and outstanding common shares will be combined into one share, with no change to authorized shares or par value. The split is primarily intended to help meet Nasdaq’s minimum bid price requirement. Immediately after effectiveness, approximately 592,373 shares of common stock will be outstanding. Fractional shares will be settled in cash, and equity awards and warrants will be proportionately adjusted. BIAF will keep its ticker, and the common stock will have a new CUSIP 09076W406.